Eli Lilly hits $1T market cap as GLP-1 hype rivals AI
Eli Lilly’s entry into the $1 trillion club has turned a century-old drugmaker into the market’s newest momentum story, powered less by traditional pharma pipelines than by a cultural obsession with weight loss. The surge in appetite for GLP-1 drugs has pushed the company into the same valuation stratosphere as the biggest technology names, forcing…